Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development
J Clin Oncol
.
2012 Dec 20;30(36):4584-6; author reply 4588-9.
doi: 10.1200/JCO.2012.44.1022.
Epub 2012 Nov 19.
Authors
Douglas Yee
,
Tufia Haddad
,
Kathy Albain
,
Anna Barker
,
Christopher Benz
,
Judy Boughey
,
Meredith Buxton
,
Amy Jo Chien
,
Angela DeMichele
,
David Dilts
,
Anthony Elias
,
Paul Haluska
,
Michael Hogarth
,
Alan Hu
,
Nola Hytlon
,
Henry G Kaplan
,
Gary G Kelloff
,
Qamar Khan
,
Julie Lang
,
Brian Leyland-Jones
,
Minetta Liu
,
Rita Nanda
,
Donald Northfelt
,
Olufunmilayo I Olopade
,
John Park
,
Barbara Parker
,
David Parkinson
,
Sonia Pearson-White
,
Jane Perlmutter
,
Lajos Pusztai
,
Fraser Symmans
,
Hope Rugo
,
Debu Tripathy
,
Anne Wallace
,
David Wholley
,
Laura Van't Veer
,
Donald A Berry
,
Laura Esserman
PMID:
23169510
DOI:
10.1200/JCO.2012.44.1022
No abstract available
Publication types
Letter
Comment
MeSH terms
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Breast Neoplasms / therapy*
Carcinoma in Situ / therapy*
Carcinoma, Ductal, Breast / therapy*
Female
Humans
Mastectomy*
Neoadjuvant Therapy*